T. Rowe Price Associates, Inc. 13D and 13G filings for Soleno Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 1:07 pm Purchase | 2025-06-30 | 13G | Soleno Therapeutics, Inc. SLNO | T. Rowe Price Associates, Inc. | 3,461,510 6.900% | 1,060,722 (+44.18%) | Filing |
| 2025-05-14 10:45 am Purchase | 2025-03-31 | 13G | Soleno Therapeutics, Inc. SLNO | T. Rowe Price Associates, Inc. | 2,400,788 5.200% | 2,400,788 (New Position) | Filing |